Business Wire

Takeda Named Global Top Employer for Sixth Consecutive Year

Share

Takeda ( TSE:4502/NYSE:TAK ) today announced that, for the sixth consecutive year, it was one of only 15 companies to achieve global Top Employer® certification for 2023. In addition to the global certification, Takeda is also recognized as a Top Employer across 22 countries, strengthening its commitment to creating a diverse, equitable and inclusive working environment and an exceptional employee experience.

The Top Employers Institute program certifies organizations based on the participation and results of their HR Best Practices Survey. This survey covers six HR domains consisting of 20 topics including People Strategy, Work Environment, Talent Acquisition, Learning, Diversity & Inclusion, Well-being and more.

“We are steadfast in our commitment to creating a culture that fosters collaboration, well-being and resilience, and this recognition as a global top employer by the Top Employers Institute further underscores that focus,” said Lauren Duprey, chief human resources officer, Takeda. “The work we do transforms lives, helping patients around the world with little to no treatment options, and our people are at the cornerstone of everything we accomplish. Our people do business with a purpose and we are proud to provide them a work environment that enables their success.”

“Exceptional times bring out the best in people and organizations, and we have witnessed this in our Top Employers Certification Program this year: an exceptional performance from the certified Top Employers 2023. Amongst this community of outstanding organizations, Takeda, has proven its commitment to its employees on a global scale,” said David Plink, chief executive officer, Top Employers Institute. “This consistency in people practices across the globe characterizes an exclusive group of companies that have achieved a global certification through the Top Employers Program. We are proud to announce and celebrate these companies and their achievement in 2023.”

Takeda excelled globally in the areas of Ethics & Integrity, Purpose & Values, Business Strategy, Employer Branding and Organization & Change. Each of the 22 Takeda countries and regions that participated in the Top Employer survey received certification, including Canada for the first time. The full list of countries where Takeda was named a Top Employer is below:

  • Asia Pacific: Australia, China, India, Japan, South Korea
  • Europe: Austria, France, Germany, Ireland, Italy, Poland, Portugal, Spain, Switzerland, United Kingdom.
  • Latin America: Argentina, Brazil, Colombia, Mexico
  • Middle East: Israel
  • North America: Canada and United States

To learn more about Top Employers Institute and the Top Employers certification, please visit: https://www.top-employers.com.

About Takeda
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI), with expertise in immune and inflammatory diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Japanese Media
Jun Saito
jun.saito@takeda.com

U.S. and International Media
Megan Ostrower
megan.ostrower@takeda.com
+1 772-559-4924

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Novaliq Plans to File a Markting Authorisation Application for CyclASol® in the E.U. for the Treatment of Dry Eye Disease in July 20238.2.2023 16:00:00 EET | Press release

Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced its plans for filing a Marketing Authorisation Application (MAA) for CyclASol® (ciclosporin ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment of dry eye disease (DED) in the European Union. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) determined that CyclASol® is eligible to be reviewed in a centralized procedure to receive a Union Marketing Authorisation for the European Economic Area (EEA). In December 2022, EMA stated in its response that, based on the documentation provided by Novaliq, a submission is in the interest of patients at Community level under Article 3(2)b - Interest of patients of Regulation (EC) No 726/2004. Consequently, Novaliq has submitted a letter of intent to EMA to file the MAA in July 2023. Dry eye is one of the most

The IKEA Foundation Commits €10 Million to Provide Emergency Assistance in Türkiye and Northern Syria8.2.2023 15:50:00 EET | Press release

The donation will go to Médecins Sans Frontières’ (MSF) emergency fund to provide life saving care where medical needs are the greatest. This will support the delivery of essential aid, including medical assistance, psychological support and healthcare services to those most impacted by the devastating earthquake. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230208005519/en/ Image credit: Médecins Sans Frontières, Photographer: Omar Haj Kadour (Photo: Business Wire) The IKEA Foundation is also speaking with other partners who are operating in the region. These partners are coordinating with Turkish authorities to understand further needs and opportunities to provide additional assistance. This includes discussions with Better Shelter, looking at ways to provide modular temporary housing units in Türkiye and Syria. Per Heggenes, CEO of the IKEA Foundation, said: “We are deeply saddened by the devastation and loss of life

New Peer Reviewed Research Reinforces the Carbon Neutrality of Sustainably Sourced Biomass in the U.S. Southeast8.2.2023 15:00:00 EET | Press release

Enviva Inc. (NYSE: EVA), the world’s leading producer of sustainably sourced woody biomass, along with the U.S. Industrial Pellet Association (USIPA), welcome a recent study, titled “Impacts of the US southeast wood pellet industry on local forest carbon stocks.” The study has been peer-reviewed and published in a leading scientific journal, Nature, confirming that the wood pellet industry has met the overall condition of forest carbon neutrality in the U.S. Southeast between 2000 and 2019. According to the International Energy Agency (IEA), if harvest volumes (for wood products and energy) and losses related to mortality and disturbances do not exceed the growth across the whole forest, there is no net reduction in forest carbon stock. The 2022 study in Nature additionally confirms, by data, that carbon neutrality guidelines have been met by biomass producers in the U.S. Southeast, which is the world’s leading region for wood pellet production and export. Between 2000 and 2019, data a

Adrestia Therapeutics Partners with Leading Patient Advocacy Groups to Form Ataxia Telangiectasia Research Consortium8.2.2023 15:00:00 EET | Press release

Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced it has co-founded a research consortium to find new treatments for ataxia telangiectasia (AT), a fatal, inherited, progressive neurodegenerative disorder that is typically diagnosed in young children. The consortium’s other founding members include the A-T Children’s Project, the AT Society and Action for AT. Adrestia is applying its synthetic rescue technology to systematically mine the human genome for novel targets which could be used as the basis for therapies for AT and related diseases. Currently, there are no corrective therapies for AT. “The entire Adrestia team is moved by the dedication of the AT community and we are honored to be working closely with our consortium partners to combine patient networks, scientific and other resources to accelerate the development of new treatment options, for which there is a desperate need,” said Robert Johnson, Chief Executive Officer of Adre

Rovensa Group Launches Rovensa Next, a New Global Biosolutions Business Unit to Shape a Sustainable Future for Agriculture8.2.2023 13:44:00 EET | Press release

Faced with global challenges due to a growing population and climate change, among others, farmers need a solution to feed the planet through healthy and safe solutions. Today, Rovensa Group, a global leader of agricultural inputs for sustainable agriculture, answers that need with Rovensa Next, a new global business unit dedicated to biosolutions for agriculture that aims to give back to the Earth what the Earth gives to us. Rovensa Next makes its debut this week at Fruit Logistica Berlin (Hall 1.2, Stand B-50), the leading trade fair for the fresh fruit industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230208005486/en/ José Alfredo García, Co-COO Rovensa Next, Javier Calleja, incoming CEO Rovensa Group, Eric van Innis, CEO Rovensa Group and Carlos Ledó, Co-COO Rovensa Next (Photo: Business Wire) Rovensa Next aggregates ten Rovensa Group companies, creating a holistic platform of innovative biosolutions to shape a su

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom